Skin Cancer

Factors of Ipilimumab/Nivolumab Success in Metastatic Melanoma Identified

September 12th 2021, 1:00pm


This new analysis of combination treatment with ipilimumab and nivolumab identified factors likely to lead to therapeutic success with the combination.

In BRAF-Mutated Advanced Melanoma, Range of First-line Choices Brings Hope, Questions

September 10th 2021, 11:10am


Patients with BRAF-V600 mutated metastatic melanoma have new treatment options to consider, but scientists are still waiting on additional data to help choose which first-line treatments are best for which patients.

Dr Christine Ko: Transplant Patients Face Unique Skin Cancer Risks

September 10th 2021, 11:00am


Patients who undergo transplant face an increased risk of skin cancer because of their immunosuppressed status, explained Christine Ko, MD, professor of dermatology and pathology at Yale University.

Similar Therapy Tolerance Seen Among Patients With Melanoma, Regardless of Age

September 8th 2021, 7:00pm


Patients over the age of 65 had similar rates of serious adverse events, and nearly identical progression-free survival, when compared with younger patients.

Dr Todd Schlesinger on How Medical, Cosmetic, Research Dermatology Interact

September 5th 2021, 12:00pm


Being a full-service dermatology practice helps make patients' lives easier when they have skin cancer, explained Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

Higher Rates of Chronic Complications Linked With Anti–PD-1 Treatment Seen in Patients With Melanoma

August 31st 2021, 3:12pm


Results of a multicenter study showed 43% of patients with advanced melanoma treated with anti–programmed cell death 1 therapy experienced chronic complications.

Autophagy Inhibition in BRAF-Driven Skin Cancers Raises Hopes, Questions

August 25th 2021, 7:00pm


Autophagy inhibition could help patients who develop resistance to BRAF inhibitors, but a new review shows important questions remain.

Researchers Assess ICI Resistance in Melanoma Treatment

August 22nd 2021, 3:30pm


Researchers outline factors that may inhibit immune checkpoint inhibitor efficacy in patients with melanoma.

Dr Todd Schlesinger: Morphology, Immunosuppression Affect Actinic Keratosis Outcomes

August 19th 2021, 12:00pm


Actinic keratosis outcomes can be affected by several variables, and these lesions need to be treated to minimize progression risk, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

New Research Aims to Solve Resistance Problems in Melanoma Therapies

August 15th 2021, 1:00pm


New strategies are currently being investigated to find out how to avoid resistance to immune checkpoint inhibitors and BRAF/MEK inhibitors.